Table 1 |.
Baseline patient characteristics
| Characteristic | MSK (n=1,002) | Sydney (n=125) | Total (n=1,127) |
|---|---|---|---|
| Age, median (IQR), years | 68 (59–75) | 67 (57–74) | 68 (59–75) |
| Sex, n (% total) | |||
| Men | 432 (43%) | 48 (38%) | 480 (43%) |
| Women | 570 (57%) | 77 (62%) | 647 (57%) |
| Race, n (% total) | |||
| White | 730 (73%) | 37 (30%) | 767 (68%) |
| Asian | 164 (16%) | 34 (27%) | 196 (17%) |
| Black | 53 (5%) | 0 (0%) | 53 (5%) |
| Other | 20 (2%) | 0 (0%) | 20 (2%) |
| Unknown | 35 (3%) | 54 (43%) | 89 (8%) |
| Histology, n (% total) | |||
| Adenocarcinoma | 849 (85%) | 120 (96%) | 969 (86%) |
| Squamous | 84 (8%) | 4 (3%) | 88 (8%) |
| Othera | 69 (7%) | 1 (1%) | 70 (6%) |
| Smoking history, n (% total) | |||
| Current/former | 553 (55%) | 42 (34%) | 595 (53%) |
| Never | 449 (45%) | 66 (53%) | 515 (46%) |
| Unknown | 0 (0%) | 17 (14%) | 17 (2%) |
| Treatment history, n (% total) | |||
| Treatment naive | 677 (68%) | 51 (41%) | 728 (65%) |
| Previous treatment | 325 (32%) | 74 (59%) | 399 (35%) |
| Previous targeted therapy | 152 (15%) | 49 (39%) | 201 (18%) |
| Previous nontargeted therapy | 173 (17%) | 25 (20%) | 198 (17%) |
| Additional sequencing, n (% total) | |||
| MSK-ACCESS | 230 (23%) | NA | 230 (20%) |
| Within 30 days | 163 (16%) | NA | 163 (14%) |
| MSK-IMPACT | 676 (67%) | NA | 676 (60%) |
| Within 30 days | 429 (43%) | NA | 429 (38%) |
| Other tissue sequencing | 129 (13%) | 112 (90%) | 241 (21%) |
| No tissue sequencingb | 197 (20%) | 12 (10%) | 209 (19%) |
| Concurrent PET, n (% total) | MSK (n=337) | Sydney (n=120) | Total (n=457) |
| Extrapulmonary disease | 252 (75%) | 83 (69%) | 335 (73%) |
| No extrapulmonary disease | 85 (25%) | 37 (31%) | 122 (27%) |
a
Includes dedifferentiated, neuroendocrine and mixed histologic subtypes.
b
Reasons included an inability to collect samples from the patient or an outside institution, insufficient material or sequencing failure.